{"id":745413,"date":"2016-02-22T08:00:00","date_gmt":"2016-02-22T08:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-once-daily-formulation-of-isentress-raltegravir-meets-primary-and-secondary-endpoints-in-pivotal-phase-3-study\/"},"modified":"2025-11-07T01:25:58","modified_gmt":"2025-11-07T06:25:58","slug":"mercks-investigational-once-daily-formulation-of-isentress-raltegravir-meets-primary-and-secondary-endpoints-in-pivotal-phase-3-study","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-once-daily-formulation-of-isentress-raltegravir-meets-primary-and-secondary-endpoints-in-pivotal-phase-3-study\/","title":{"rendered":"Merck\u2019s Investigational Once-Daily Formulation of ISENTRESS\u00ae (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study"},"content":{"rendered":"<p class=\"bwalignc\">       Results to be Presented at Future Medical Meeting, and Regulatory        Submissions Planned for 2016     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced top-line results from the company\u2019s Phase 3 pivotal<br \/>\n      trial, ONCEMRK. ONCEMRK is evaluating an investigational once-daily<br \/>\n      formulation of ISENTRESS<sup>\u00ae<\/sup><b> <\/b>(raltegravir), known as<br \/>\n      raltegravir 600 mg (to be given as 2 x 600 mg once-daily), for<br \/>\n      previously untreated HIV-1 infected adults. The study met its primary<br \/>\n      efficacy endpoint: 1200 mg raltegravir (given as 2 x 600 mg once-daily)<br \/>\n      was statistically non-inferior to the marketed formulation approved dose<br \/>\n      of ISENTRESS 400 mg twice-daily, each in combination therapy with<br \/>\n      TRUVADA\u2122, as assessed by the proportion of patients achieving HIV-1 RNA<br \/>\n      &lt;40 copies\/mL at Week 48. In addition, the secondary endpoints of<br \/>\n      tolerability and immunologic efficacy (as measured by change from<br \/>\n      baseline in CD4 cell counts at Week 48) were comparable.&nbsp;Later this<br \/>\n      year, Merck plans to present detailed findings of the study at an<br \/>\n      upcoming scientific conference, and to submit applications for licensure<br \/>\n      to the U.S. Food and Drug Administration and the European Medicines<br \/>\n      Agency for this investigational new formulation.\n    <\/p>\n<p>\n      ISENTRESS is indicated twice-daily in combination with other<br \/>\n      antiretroviral agents for the treatment of HIV-1 infection in patients 4<br \/>\n      weeks of age and older. The use of other active agents with ISENTRESS is<br \/>\n      associated with a greater likelihood of treatment response.\n    <\/p>\n<p>\n      \u201cMerck has never wavered in our commitment to develop meaningful<br \/>\n      therapeutic options for people with HIV-1 infection,\u201d said Dr. Eliav<br \/>\n      Barr, vice president clinical development, infectious diseases, Merck<br \/>\n      Research Laboratories. &#8220;We are pleased that this study has met its<br \/>\n      primary endpoint and look forward to presenting the data at a future<br \/>\n      congress.\u201d\n    <\/p>\n<p>\n      <b>About ONCEMRK<\/b>\n    <\/p>\n<p>\n      The ongoing Phase 3 multicenter, double-blind, randomized, active<br \/>\n      comparator-controlled clinical trial is evaluating the efficacy and<br \/>\n      safety of raltegravir 1200 mg (given as 2 x 600 mg) once-daily compared<br \/>\n      to ISENTRESS 400 mg twice-daily each in combination therapy with<br \/>\n      TRUVADA\u2122 in previously untreated HIV-1 infected adult patients. The<br \/>\n      primary efficacy objective is the proportion of patients achieving HIV<br \/>\n      RNA &lt;40 copies\/mL at Week 48. Secondary objectives included change from<br \/>\n      baseline in CD4 cell counts and tolerability at Week 48. The newly<br \/>\n      formulated 600 mg tablet for once-daily use (2 x 600 mg), in this study,<br \/>\n      is not currently approved for use and this formulation is not<br \/>\n      interchangeable with the currently marketed 400 mg tablet.\n    <\/p>\n<p>\n      The planned total treatment duration for this study is 96 weeks.\n    <\/p>\n<p>\n      For further information regarding ONCEMRK please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02131233&amp;esheet=51284158&amp;newsitemid=20160222005750&amp;lan=en-US&amp;anchor=clinicaltrials.gov&amp;index=1&amp;md5=5b861d276b61246391d36e164f4100c3\" rel=\"nofollow\">clinicaltrials.gov<\/a>.,<br \/>\n      clinical trial registry number NCT02131233.\n    <\/p>\n<p>\n      <b>Important Selected Safety Information<\/b>\n    <\/p>\n<p>\n      ISENTRESS does not cure HIV-1 infection or AIDS.\n    <\/p>\n<p>\n      Severe, potentially life-threatening and fatal skin reactions have been<br \/>\n      reported. This includes cases of Stevens-Johnson syndrome,<br \/>\n      hypersensitivity reaction and toxic epidermal necrolysis. Immediately<br \/>\n      discontinue treatment with ISENTRESS and other suspect agents if severe<br \/>\n      hypersensitivity, severe rash, or rash with systemic symptoms or liver<br \/>\n      aminotransferase elevations develops and monitor clinical status,<br \/>\n      including liver aminotransferases closely.\n    <\/p>\n<p>\n      Immune reconstitution syndrome can occur, including the occurrence of<br \/>\n      autoimmune disorders with variable time to onset, which may necessitate<br \/>\n      further evaluation and treatment.\n    <\/p>\n<p>\n      ISENTRESS chewable tablets contain phenylalanine, a component of<br \/>\n      aspartame, which may be harmful to patients with phenylketonuria.\n    <\/p>\n<p>\n      Coadministration of ISENTRESS with drugs that are strong inducers of<br \/>\n      uridine diphosphate glucuronosyltransferase (UGT) 1A1 may result in<br \/>\n      reduced plasma concentrations of raltegravir. Coadministration of<br \/>\n      ISENTRESS (raltegravir) with drugs that inhibit UGT1A1 may increase<br \/>\n      plasma levels of raltegravir.\n    <\/p>\n<p>\n      Coadministration of ISENTRESS and other drugs may alter the plasma<br \/>\n      concentration of raltegravir. The potential for drug-drug interactions<br \/>\n      must be considered prior to and during therapy. Coadministration or<br \/>\n      staggered administration of aluminum and\/or magnesium<br \/>\n      hydroxide-containing antacids and ISENTRESS is not recommended.\n    <\/p>\n<p>\n      Rifampin, a strong inducer of UGT1A1, reduces plasma concentrations of<br \/>\n      ISENTRESS. Therefore, the dose of ISENTRESS for adults should be<br \/>\n      increased to 800 mg twice daily during coadministration with rifampin.<br \/>\n      There are no data to guide coadministration of ISENTRESS with rifampin<br \/>\n      in patients below 18 years of age.\n    <\/p>\n<p>\n      The most commonly reported (\u22652%) drug-related clinical adverse reactions<br \/>\n      of moderate to severe intensity in treatment-na\u00efve adult patients<br \/>\n      receiving ISENTRESS compared with efavirenz were insomnia (4% vs 4%),<br \/>\n      headache (4% vs 5%), nausea (3% vs 4%), fatigue (2% vs 3%), and<br \/>\n      dizziness (2% vs 6%) respectively. In treatment-experienced adult<br \/>\n      patients receiving ISENTRESS, the most commonly reported (\u22652%)<br \/>\n      drug-related clinical adverse reactions of moderate to severe intensity<br \/>\n      and at a higher incidence compared with placebo was headache (2% vs<br \/>\n      &lt;1%). In both studies, intensities were defined as: Moderate (discomfort<br \/>\n      enough to cause interference with usual activity); or Severe<br \/>\n      (incapacitating with inability to work or do usual activity). In<br \/>\n      treatment-experienced pediatric patients 4 weeks through 18 years of age<br \/>\n      receiving ISENTRESS, the frequency, type and severity of drug-related<br \/>\n      adverse reactions were comparable to those observed in adults.\n    <\/p>\n<p>\n      Grade 2-4 creatine kinase laboratory abnormalities were observed in<br \/>\n      subjects treated with ISENTRESS. Myopathy and rhabdomyolysis have been<br \/>\n      reported. Use with caution in patients at increased risk of myopathy or<br \/>\n      rhabdomyolysis, such as patients receiving concomitant medications known<br \/>\n      to cause these conditions and patients with a history of rhabdomyolysis,<br \/>\n      myopathy or increased serum creatine kinase.\n    <\/p>\n<p>\n      Rash occurred more commonly in treatment-experienced subjects receiving<br \/>\n      regimens containing ISENTRESS + darunavir\/ritonavir compared to subjects<br \/>\n      receiving ISENTRESS without darunavir\/ritonavir or darunavir\/ritonavir<br \/>\n      without ISENTRESS. However, rash that was considered drug related<br \/>\n      occurred at similar rates for all 3 groups. These rashes were mild to<br \/>\n      moderate in severity and did not limit therapy; there were no<br \/>\n      discontinuations due to rash.\n    <\/p>\n<p>\n      ISENTRESS should be used during pregnancy only if the potential benefit<br \/>\n      justifies the potential risk to the fetus. There are no adequate and<br \/>\n      well-controlled studies in pregnant women. In addition, there have been<br \/>\n      no pharmacokinetic studies conducted in pregnant patients.\n    <\/p>\n<p>\n      To monitor maternal-fetal outcomes of pregnant patients exposed to<br \/>\n      ISENTRESS, an Antiretroviral Pregnancy Registry has been established.<br \/>\n      Physicians are encouraged to register patients by calling 1-800-258-4263.\n    <\/p>\n<p>\n      <b>About ISENTRESS (raltegravir)<\/b>\n    <\/p>\n<p>\n      ISENTRESS is Merck&#8217;s integrase inhibitor for the treatment of HIV-1<br \/>\n      infection in adult and pediatric patients ages four weeks and older and<br \/>\n      weighing at least 3 kg as part of combination HIV therapy. ISENTRESS<br \/>\n      works by inhibiting the insertion of HIV-1 DNA into human DNA by the<br \/>\n      integrase enzyme and has demonstrated rapid antiviral activity.<br \/>\n      Inhibiting integrase from performing this essential function limits the<br \/>\n      ability of the virus to replicate and infect new cells.\n    <\/p>\n<p>\n      ISENTRESS is approved as part of combination therapy in 115 countries<br \/>\n      for treatment of HIV-1 infection in adult patients. ISENTRESS, in<br \/>\n      combination therapy, for use in children and adolescents with HIV-1 ages<br \/>\n      two years and older has also been approved for use in 64 countries, and<br \/>\n      ISENTRESS oral suspension for infants at least four weeks of age is<br \/>\n      approved for use in 34 countries. Please refer to the Prescribing<br \/>\n      Information for ISENTRESS for information about dosage and<br \/>\n      administration for each formulation.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51284158&amp;newsitemid=20160222005750&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=f68989a551c9753258aa4f0b97ddb4e0\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51284158&amp;newsitemid=20160222005750&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=c484056d9e7685a42b561c7988c77ff0\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51284158&amp;newsitemid=20160222005750&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=cd60d72483d4dd9b468cc85b8aad5d0a\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51284158&amp;newsitemid=20160222005750&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=1d73ed63785f9b5889df1769923766c6\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51284158&amp;newsitemid=20160222005750&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=b52999ba1d1fe9fe330b1769d3a5a4cd\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co. Inc., Kenilworth, NJ, USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, NJ, USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51284158&amp;newsitemid=20160222005750&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=e2fe97226e8f74b30a20419678c9b075\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for ISENTRESS (raltegravir) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_pi.pdf&amp;esheet=51284158&amp;newsitemid=20160222005750&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_pi.pdf&amp;index=8&amp;md5=0332b905105631af834ee1a3184e339d\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/i\/isentress\/isentress_pi.pdf<\/b><\/a><b>,<br \/>\n      Patient Information for ISENTRESS at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_ppi.pdf&amp;esheet=51284158&amp;newsitemid=20160222005750&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_ppi.pdf&amp;index=9&amp;md5=ecf28e91f50933688c59af60242009bc\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/i\/isentress\/isentress_ppi.pdf<\/b><\/a><b><br \/>\n      and Instructions for Use of ISENTRESS (raltegravir) for Oral Suspension<br \/>\n      at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_ifu.pdf&amp;esheet=51284158&amp;newsitemid=20160222005750&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_ifu.pdf&amp;index=10&amp;md5=c4d64dd941f8a5ec22ea8ea9d18fbb05\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/i\/isentress\/isentress_ifu.pdf<\/b><\/a>\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160222005750r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       For Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Carmen        de Gourville, 267-305-4195<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Results to be Presented at Future Medical Meeting, and Regulatory Submissions Planned for 2016 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced top-line results from the company\u2019s Phase 3 pivotal trial, ONCEMRK. ONCEMRK is evaluating an investigational once-daily formulation of ISENTRESS\u00ae (raltegravir), known as raltegravir 600 mg (to be given as 2 x 600 mg once-daily), for previously untreated HIV-1 infected adults. The study met its primary efficacy endpoint: 1200 mg raltegravir (given as 2 x 600 mg once-daily) was statistically non-inferior to the marketed formulation approved dose of ISENTRESS 400 mg twice-daily, each in combination therapy with TRUVADA\u2122, as assessed by the proportion of patients achieving HIV-1 RNA &lt;40 copies\/mL at Week 48. In addition, the secondary endpoints of tolerability and immunologic efficacy (as measured by change from baseline in CD4 cell counts at Week 48) were comparable.&nbsp;Later this year, Merck plans to<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745413","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s Investigational Once-Daily Formulation of ISENTRESS\u00ae (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-once-daily-formulation-of-isentress-raltegravir-meets-primary-and-secondary-endpoints-in-pivotal-phase-3-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s Investigational Once-Daily Formulation of ISENTRESS\u00ae (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Results to be Presented at Future Medical Meeting, and Regulatory Submissions Planned for 2016 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced top-line results from the company\u2019s Phase 3 pivotal trial, ONCEMRK. ONCEMRK is evaluating an investigational once-daily formulation of ISENTRESS\u00ae (raltegravir), known as raltegravir 600 mg (to be given as 2 x 600 mg once-daily), for previously untreated HIV-1 infected adults. The study met its primary efficacy endpoint: 1200 mg raltegravir (given as 2 x 600 mg once-daily) was statistically non-inferior to the marketed formulation approved dose of ISENTRESS 400 mg twice-daily, each in combination therapy with TRUVADA\u2122, as assessed by the proportion of patients achieving HIV-1 RNA &lt;40 copies\/mL at Week 48. In addition, the secondary endpoints of tolerability and immunologic efficacy (as measured by change from baseline in CD4 cell counts at Week 48) were comparable.&nbsp;Later this year, Merck plans to\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-once-daily-formulation-of-isentress-raltegravir-meets-primary-and-secondary-endpoints-in-pivotal-phase-3-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-once-daily-formulation-of-isentress-raltegravir-meets-primary-and-secondary-endpoints-in-pivotal-phase-3-study\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-once-daily-formulation-of-isentress-raltegravir-meets-primary-and-secondary-endpoints-in-pivotal-phase-3-study\\\/\",\"name\":\"Merck\u2019s Investigational Once-Daily Formulation of ISENTRESS\u00ae (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-02-22T08:00:00+00:00\",\"dateModified\":\"2025-11-07T06:25:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-once-daily-formulation-of-isentress-raltegravir-meets-primary-and-secondary-endpoints-in-pivotal-phase-3-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-once-daily-formulation-of-isentress-raltegravir-meets-primary-and-secondary-endpoints-in-pivotal-phase-3-study\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-once-daily-formulation-of-isentress-raltegravir-meets-primary-and-secondary-endpoints-in-pivotal-phase-3-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s Investigational Once-Daily Formulation of ISENTRESS\u00ae (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s Investigational Once-Daily Formulation of ISENTRESS\u00ae (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-once-daily-formulation-of-isentress-raltegravir-meets-primary-and-secondary-endpoints-in-pivotal-phase-3-study\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s Investigational Once-Daily Formulation of ISENTRESS\u00ae (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study - Merck.com","og_description":"Results to be Presented at Future Medical Meeting, and Regulatory Submissions Planned for 2016 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced top-line results from the company\u2019s Phase 3 pivotal trial, ONCEMRK. ONCEMRK is evaluating an investigational once-daily formulation of ISENTRESS\u00ae (raltegravir), known as raltegravir 600 mg (to be given as 2 x 600 mg once-daily), for previously untreated HIV-1 infected adults. The study met its primary efficacy endpoint: 1200 mg raltegravir (given as 2 x 600 mg once-daily) was statistically non-inferior to the marketed formulation approved dose of ISENTRESS 400 mg twice-daily, each in combination therapy with TRUVADA\u2122, as assessed by the proportion of patients achieving HIV-1 RNA &lt;40 copies\/mL at Week 48. In addition, the secondary endpoints of tolerability and immunologic efficacy (as measured by change from baseline in CD4 cell counts at Week 48) were comparable.&nbsp;Later this year, Merck plans to","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-once-daily-formulation-of-isentress-raltegravir-meets-primary-and-secondary-endpoints-in-pivotal-phase-3-study\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:58+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-once-daily-formulation-of-isentress-raltegravir-meets-primary-and-secondary-endpoints-in-pivotal-phase-3-study\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-once-daily-formulation-of-isentress-raltegravir-meets-primary-and-secondary-endpoints-in-pivotal-phase-3-study\/","name":"Merck\u2019s Investigational Once-Daily Formulation of ISENTRESS\u00ae (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-02-22T08:00:00+00:00","dateModified":"2025-11-07T06:25:58+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-once-daily-formulation-of-isentress-raltegravir-meets-primary-and-secondary-endpoints-in-pivotal-phase-3-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-once-daily-formulation-of-isentress-raltegravir-meets-primary-and-secondary-endpoints-in-pivotal-phase-3-study\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-once-daily-formulation-of-isentress-raltegravir-meets-primary-and-secondary-endpoints-in-pivotal-phase-3-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s Investigational Once-Daily Formulation of ISENTRESS\u00ae (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"01206922-dfb0-42a8-9c86-b8695c3ac630","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-Investigational-Once-Daily-Formulation-of-ISENTRESS-raltegravir-Meets-Primary-and-Secondary-Endpoints-in-Pivotal-Phase-3-Study-2016.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745413\/revisions"}],"predecessor-version":[{"id":3674804,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745413\/revisions\/3674804"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745413"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}